Mario Cazzola

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/949847/publications.pdf

Version: 2024-02-01

542 papers	54,990 citations	1368 108 h-index	1413 221 g-index
559 all docs	559 docs citations	559 times ranked	27821 citing authors

#	Article	IF	Citations
1	The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016, 127, 2391-2405.	0.6	7,429
2	A Gain-of-Function Mutation ofJAK2in Myeloproliferative Disorders. New England Journal of Medicine, 2005, 352, 1779-1790.	13.9	3,240
3	Revised International Prognostic Scoring System for Myelodysplastic Syndromes. Blood, 2012, 120, 2454-2465.	0.6	2,458
4	Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms. New England Journal of Medicine, 2013, 369, 2379-2390.	13.9	1,698
5	Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood, 2013, 122, 3616-3627.	0.6	1,562
6	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. New England Journal of Medicine, 2013, 369, 111-121.	13.9	1,284
7	SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts. New England Journal of Medicine, 2011, 365, 1384-1395.	13.9	1,094
8	Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 2007, 25, 3503-3510.	0.8	969
9	International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood, 2022, 140, 1200-1228.	0.6	814
10	A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 2010, 115, 1703-1708.	0.6	805
11	Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. Journal of Clinical Oncology, 2005, 23, 7594-7603.	0.8	804
12	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	3.3	653
13	Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood, 2013, 122, 2943-2964.	0.6	567
14	Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia, 2013, 27, 1874-1881.	3.3	540
15	JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood, 2014, 123, 1544-1551.	0.6	507
16	Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood, 2011, 118, 6239-6246.	0.6	457
17	Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood, 2014, 123, 3247-3254.	0.6	428
18	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, 118, 3765-3776.	0.6	424

#	Article	IF	Citations
19	Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. American Journal of Medicine, 2004, 117, 755-761.	0.6	415
20	Clinical significance of somatic mutation in unexplained blood cytopenia. Blood, 2017, 129, 3371-3378.	0.6	379
21	MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. Journal of Clinical Oncology, 2018, 36, 310-318.	0.8	373
22	Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nature Medicine, 2020, 26, 1549-1556.	15.2	372
23	SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood, 2015, 126, 233-241.	0.6	361
24	Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 2014, 124, 1062-1069.	0.6	340
25	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	13.9	335
26	A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia, 2010, 24, 1574-1579.	3.3	321
27	Myelodysplastic Syndromes â€" Coping with Ineffective Hematopoiesis. New England Journal of Medicine, 2005, 352, 536-538.	13.9	306
28	The genetic basis of myelodysplasia and its clinical relevance. Blood, 2013, 122, 4021-4034.	0.6	294
29	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in WaldenstrÃ¶mâ€™s macroglobulinemia and related lymphoid neoplasms. Blood, 2013, 121, 2522-2528.	0.6	290
30	Diagnosis and classification of myelodysplastic syndrome: International Working Group on Morphology of myelodysplastic syndrome (IWGM-MDS) consensus proposals for the definition and enumeration of myeloblasts and ring sideroblasts. Haematologica, 2008, 93, 1712-1717.	1.7	281
31	Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 383, 1358-1374.	13.9	274
32	Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells InÂVivo. Cancer Cell, 2014, 25, 794-808.	7.7	272
33	Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With Improved Survival in Myelodysplastic Syndrome. Journal of Clinical Oncology, 2008, 26, 3607-3613.	0.8	270
34	Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis. Journal of Clinical Oncology, 2013, 31, 2662-2670.	0.8	265
35	Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. Blood, 2008, 111, 1686-1689.	0.6	264
36	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	3.3	263

#	Article	IF	Citations
37	Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. , 2022, 1, .		259
38	Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013, 121, 3005-3015.	0.6	251
39	Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia, 2010, 24, 756-764.	3.3	250
40	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. Blood, 2016, 128, 1408-1417.	0.6	249
41	Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica, 2011, 96, 1433-1440.	1.7	247
42	Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure. European Heart Journal, 2005, 26, 2232-2237.	1.0	246
43	Use of Recombinant Human Erythropoietin Outside the Setting of Uremia. Blood, 1997, 89, 4248-4267.	0.6	244
44	A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia, 2017, 31, 2726-2731.	3.3	242
45	Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood, 2006, 107, 3676-3682.	0.6	236
46	Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia, 2010, 24, 1062-1065.	3.3	231
47	Juvenile Hemochromatosis Locus Maps to Chromosome 1q. American Journal of Human Genetics, 1999, 64, 1388-1393.	2.6	229
48	Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood, 2016, 127, 325-332.	0.6	228
49	Clinical Relevance of Bone Marrow Fibrosis and CD34-Positive Cell Clusters in Primary Myelodysplastic Syndromes. Journal of Clinical Oncology, 2009, 27, 754-762.	0.8	225
50	A prognostic model to predict survival in 867 World Health Organizationâ€“defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment. Blood, 2012, 120, 1197-1201.	0.6	222
51	Driver somatic mutations identify distinct disease entities within myeloid neoplasms with myelodysplasia. Blood, 2014, 124, 1513-1521.	0.6	222
52	Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 1995, 86, 4446-4453.	0.6	221
53	Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica, 2011, 96, 441-449.	1.7	220
54	Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms. Leukemia, 2016, 30, 431-438.	3.3	216

#	Article	IF	Citations
55	Relative response of patients with myelodysplastic syndromes and other transfusionâ€dependent anaemias to deferasirox (ICL670): a 1â€yr prospective study. European Journal of Haematology, 2008, 80, 168-176.	1.1	210
56	Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood, 2012, 120, 1202-1209.	0.6	205
57	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. Journal of Clinical Oncology, 2016, 34, 3627-3637.	0.8	204
58	p53 Lesions in Leukemic Transformation. New England Journal of Medicine, 2011, 364, 488-490.	13.9	202
59	Translational pathophysiology: a novel molecular mechanism of human disease. Blood, 2000, 95, 3280-3288.	0.6	201
60	Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms. Blood, 2017, 129, 680-692.	0.6	199
61	Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 50 Haematology,the, 2020, 7, e196-e208.	2.2	199
62	Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood, 2006, 108, 337-345.	0.6	198
63	Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes. Nature Communications, 2015, 6, 5901.	5.8	196
64	TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia, 2019, 33, 1747-1758.	3.3	195
65	SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood, 2020, 136, 157-170.	0.6	195
66	Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood, 2011, 117, 2813-2816.	0.6	190
67	Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica, 2008, 93, 741-752.	1.7	182
68	Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood, 1990, 75, 1903-1919.	0.6	181
69	Mitochondrial ferritin expression in erythroid cells from patients with sideroblastic anemia. Blood, 2003, 101, 1996-2000.	0.6	181
70	From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 2014, 123, 3714-3719.	0.6	174
71	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood, 1996, 87, 4824-4830.	0.6	169
72	Impact of spliceosome mutations on RNA splicing in myelodysplasia: dysregulated genes/pathways and clinical associations. Blood, 2018, 132, 1225-1240.	0.6	168

#	Article	IF	Citations
73	Spectrum of hemojuvelin gene mutations in 1q-linked juvenile hemochromatosis. Blood, 2004, 103, 4317-4321.	0.6	167
74	Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005, 106, 3374-3376.	0.6	166
75	A mutation in the TMPRSS6 gene, encoding a transmembrane serine protease that suppresses hepcidin production, in familial iron deficiency anemia refractory to oral iron. Haematologica, 2008, 93, 1473-1479.	1.7	166
76	Mitochondrial Ferritin: A New Player in Iron Metabolism. Blood Cells, Molecules, and Diseases, 2002, 29, 376-383.	0.6	165
77	A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer, 2014, 120, 513-520.	2.0	165
78	Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R. Blood, 2014, 123, 2333-2342.	0.6	162
79	Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells. Leukemia, 2015, 29, 1092-1103.	3.3	161
80	Evidence for a polyclonal nature of the cell infiltrate in sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). British Journal of Haematology, 1995, 91, 415-418.	1.2	157
81	Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood, 2010, 116, 2857-2858.	0.6	153
82	Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression. Blood, 2011, 118, 167-176.	0.6	153
83	An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood, 2015, 125, 1857-1865.	0.6	153
84	Impact of allogeneic stem cell transplantation on survival of patients less than 65 years of age with primary myelofibrosis. Blood, 2015, 125, 3347-3350.	0.6	152
85	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. Blood, 2012, 119, 188-191.	0.6	150
86	Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood, 2007, 110, 485-489.	0.6	148
87	Gene expression profiling of CD34⁺ cells in patients with the 5qâ^' syndrome. British Journal of Haematology, 2007, 139, 578-589.	1.2	146
88	Natural history of juvenile haemochromatosis. British Journal of Haematology, 2002, 117, 973-979.	1.2	145
89	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nature Communications, 2015, 6, 6691.	5.8	145
90	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. Haematologica, 2016, 101, 821-829.	1.7	140

#	Article	IF	Citations
91	Time-dependent changes in mortality and transformation risk in MDS. Blood, 2016, 128, 902-910.	0.6	140
92	Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia. Nature Communications, 2018, 9, 3649.	5.8	140
93	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	0.6	137
94	Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica, 2002, 87, 1286-306.	1.7	136
95	Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood, 2009, 114, 3538-3545.	0.6	135
96	Deletions of the transcription factor Ikaros in myeloproliferative neoplasms. Leukemia, 2010, 24, 1290-1298.	3.3	135
97	Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between Phenotypes and Specific Mutations in the Iron-Responsive Element of Ferritin Light-Chain mRNA. Blood, 1997, 90, 814-821.	0.6	131
98	Familial Chronic Myeloproliferative Disorders: Clinical Phenotype and Evidence of Disease Anticipation. Journal of Clinical Oncology, 2007, 25, 5630-5635.	0.8	130
99	Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica, 2006, 91, 1588-90.	1.7	130
100	Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood, 2013, 121, 260-269.	0.6	124
101	Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia, 2015, 29, 66-75.	3.3	122
102	NEW TOOLS FOR CLINICAL EVALUATION OF ERYTHRON FUNCTION IN MAN. British Journal of Haematology, 1992, 80, 278-284.	1.2	121
103	Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 2003, 122, 386-393.	1.2	120
104	Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial [see comments]. Blood, 1992, 79, 29-37.	0.6	118
105	Flow cytometry evaluation of erythroid dysplasia in patients with myelodysplastic syndrome. Leukemia, 2006, 20, 549-555.	3.3	118
106	Flow cytometry evaluation of erythroid and myeloid dysplasia in patients with myelodysplastic syndrome. Leukemia, 2005, 19, 776-783.	3.3	115
107	Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II study. Blood, 2014, 123, 2157-2160.	0.6	115
108	Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. Blood, 2015, 125, 499-503.	0.6	115

#	Article	IF	Citations
109	Introduction to a review series: the 2016 revision of the WHO classification of tumors of hematopoietic and lymphoid tissues. Blood, 2016, 127, 2361-2364.	0.6	115
110	The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts. PLoS ONE, 2008, 3, e1970.	1.1	113
111	A moderate transfusion regimen may reduce iron loading in beta- thalassemia major without producing excessive expansion of erythropoiesis. Transfusion, 1997, 37, 135-140.	0.8	112
112	Clinical Severity and Thermodynamic Effects of Iron-responsive Element Mutations in Hereditary Hyperferritinemia-Cataract Syndrome. Journal of Biological Chemistry, 1999, 274, 26439-26447.	1.6	111
113	A dynamic prognostic model to predict survival in postâ€“polycythemia vera myelofibrosis. Blood, 2008, 111, 3383-3387.	0.6	108
114	Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. American Journal of Hematology, 2012, 87, 245-250.	2.0	107
115	Relationship between transfusion regimen and suppression of erythropoiesis in Î²â€thalassaemia major. British Journal of Haematology, 1995, 89, 473-478.	1.2	106
116	Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM). Leukemia, 2015, 29, 1502-1513.	3.3	106
117	Hydroxyureaâ€related toxicity in 3,411 patients with Ph'â€negative MPN. American Journal of Hematology, 2012, 87, 552-554.	2.0	105
118	miRNA-mRNA integrative analysis in primary myelofibrosis CD34+ cells: role of miR-155/JARID2 axis in abnormal megakaryopoiesis. Blood, 2014, 124, e21-e32.	0.6	105
119	c-abl function in normal and chronic myelogenous leukemia hematopoiesis: in vitro studies with antisense oligomers. Leukemia, 1992, 6, 1-7.	3.3	103
120	A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. British Journal of Haematology, 1995, 90, 931-934.	1.2	100
121	Four New Mutations in the Erythroid-Specific 5-Aminolevulinate Synthase (ALAS2) Gene Causing X-Linked Sideroblastic Anemia: Increased Pyridoxine Responsiveness After Removal of Iron Overload by Phlebotomy and Coinheritance of Hereditary Hemochromatosis. Blood, 1999, 93, 1757-1769.	0.6	100
122	Juvenile idiopathic haemochromatosis: A life-threatening disorder presenting as hypogonadotropic hypogonadism. Human Genetics, 1983, 65, 149-154.	1.8	96
123	Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood, 2014, 123, 1833-1835.	0.6	95
124	Natural history of idiopathic refractory sideroblastic anemia. Blood, 1988, 71, 305-312.	0.6	94
125	Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood, 2005, 106, 247-253.	0.6	94
126	Haploinsufficiency of RPS14 in 5qâ" syndrome is associated with deregulation of ribosomalâ€and translationâ€related genes. British Journal of Haematology, 2008, 142, 57-64.	1.2	91

#	Article	IF	Citations
127	Pattern of somatic mutations in patients with WaldenstrÃ¶m macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. Haematologica, 2017, 102, 2077-2085.	1.7	90
128	The transporter ABCB7 is a mediator of the phenotype of acquired refractory anemia with ring sideroblasts. Leukemia, 2013, 27, 889-896.	3.3	89
129	Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood, 2000, 96, 4363-4365.	0.6	86
130	Somatic Mutations in MDS Patients Are Associated with Clinical Features and Predict Prognosis Independent of the IPSS-R: Analysis of Combined Datasets from the International Working Group for Prognosis in MDS-Molecular Committee. Blood, 2015, 126, 907-907.	0.6	85
131	Saporin, a ribosomeâ€inactivating protein used to prepare immunotoxins, induces cell death via apoptosis. British Journal of Haematology, 1996, 93, 789-794.	1.2	84
132	Clinical Relevance of Anemia and Transfusion Iron Overload in Myelodysplastic Syndromes. Hematology American Society of Hematology Education Program, 2008, 2008, 166-175.	0.9	84
133	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	0.6	83
134	JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer, 2006, 107, 2206-2211.	2.0	82
135	Unbalanced Xâ€chromosome inactivation in haemopoietic cells from normal women. British Journal of Haematology, 1998, 102, 996-1003.	1.2	81
136	Genetic hyperferritinaemia and reticuloendothelial iron overload associated with a three base pair deletion in the coding region of the ferroportin gene (SLC11A3). British Journal of Haematology, 2002, 119, 539-546.	1.2	80
137	Screening hepcidin for mutations in juvenile hemochromatosis: identification of a new mutation (C70R). Blood, 2004, 103, 2407-2409.	0.6	80
138	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	2.0	80
139	Red Blood Cell Precursor Mass as an Independent Determinant of Serum Erythropoietin Level. Blood, 1998, 91, 2139-2145.	0.6	79
140	Leukemic transformation of polycythemia vera. Cancer, 2005, 104, 1032-1036.	2.0	79
141	Clinical features and course of refractory anemia with ring sideroblasts associated with marked thrombocytosis. Haematologica, 2012, 97, 1036-1041.	1.7	79
142	Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood, 2014, 124, 2611-2612.	0.6	79
143	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood, 1987, 70, 1014-1019.	0.6	78
144	Biologic and clinical significance of red cell ferritin. Blood, 1983, 62, 1078-1087.	0.6	76

#	Article	IF	Citations
145	The NOTCH pathway is recurrently mutated in diffuse large B-cell lymphoma associated with hepatitis C virus infection. Haematologica, 2015, 100, 246-252.	1.7	73
146	The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP). Hematology American Society of Hematology Education Program, 2015, 2015, 299-307.	0.9	72
147	Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood, 1985, 66, 935-939.	0.6	71
148	Classification and Prognostic Evaluation of Myelodysplastic Syndromes. Seminars in Oncology, 2011, 38, 627-634.	0.8	71
149	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes. Journal of Clinical Investigation, 2017, 127, 2206-2221.	3.9	69
150	The â€˜GGCCâ€™ haplotype of JAK2 confers susceptibility to JAK2 exon 12 mutation-positive polycythemia vera. Leukemia, 2009, 23, 1924-1926.	3.3	68
151	NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG. Blood, 2013, 122, 1266-1270.	0.6	68
152	Quantitative evaluation of erythropoietic activity in dysmyelopoietic syndromes. British Journal of Haematology, 1982, 50, 55-62.	1.2	67
153	The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Haematologica, 2011, 96, 367-374.	1.7	67
154	Clinical significance of genetic aberrations in secondary acute myeloid leukemia. American Journal of Hematology, 2012, 87, 1010-1016.	2.0	67
155	Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group. Leukemia and Lymphoma, 2013, 54, 472-475.	0.6	66
156	CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood, 2014, 123, 2416-2419.	0.6	66
157	Induction of p53 and up-regulation of the p53 pathway in the human 5qâ^' syndrome. Blood, 2010, 115, 2721-2723.	0.6	65
158	Characterization of Chromosome 20q Deletions In Myeloproliferative Neoplasms Using Microarray Karyotyping and Next-Generation Sequencing. Blood, 2010, 116, 4099-4099.	0.6	65
159	Genetic and clinical heterogeneity of ferroportin disease. British Journal of Haematology, 2005, 131, 663-670.	1.2	64
160	Ring sideroblasts and sideroblastic anemias. Haematologica, 2011, 96, 789-792.	1.7	64
161	Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms. Haematologica, 2011, 96, 607-611.	1.7	64
162	Gene expression and risk of leukemic transformation in myelodysplasia. Blood, 2017, 130, 2642-2653.	0.6	64

#	Article	IF	Citations
163	Management of iron deficiency in renal anemia: guidelines for the optimal therapeutic approach in erythropoietin-treated patients. Clinical Nephrology, 1997, 48, 1-8.	0.4	64
164	Erythroid marrow function in anemic patients. Blood, 1987, 69, 296-301.	0.6	63
165	Intravenous iron therapy for severe anaemia in systemic-onset juvenile chronic arthritis. Lancet, The, 1994, 344, 1052-1054.	6.3	63
166	The JAK2ÂV617F mutation in patients with cerebral venous thrombosis. Journal of Thrombosis and Haemostasis, 2012, 10, 998-1003.	1.9	61
167	Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. American Journal of Hematology, 2013, 88, 581-588.	2.0	61
168	Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome. Leukemia, 2019, 33, 2495-2505.	3.3	61
169	Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations. British Journal of Haematology, 2008, 140, 162-168.	1.2	60
170	How I treat essential thrombocythemia. Blood, 2016, 128, 2403-2414.	0.6	60
171	Sex differences in oncogenic mutational processes. Nature Communications, 2020, 11, 4330.	5.8	60
172	Relationship between clone metrics and clinical outcome in clonal cytopenia. Blood, 2021, 138, 965-976.	0.6	58
173	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	0.6	57
174	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. Blood, 2013, 122, 2284-2285.	0.6	56
175	Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood, 2019, 134, 199-210.	0.6	54
176	Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratificationâ€"an approach to classification of patients with t-MDS. Leukemia, 2021, 35, 835-849.	3.3	54
177	Prediction of response to recombinant human erythropoietin (rHuEpo) in anemia of malignancy. Haematologica, 1996, 81, 434-41.	1.7	54
178	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. American Journal of Hematology, 2020, 95, 156-166.	2.0	53
179	JAK Inhibitor in CALR-Mutant Myelofibrosis. New England Journal of Medicine, 2014, 370, 1168-1169.	13.9	52
180	Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood, 2017, 130, 1768-1771.	0.6	52

#	Article	IF	Citations
181	Defective interaction of mutant calreticulin and SOCE in megakaryocytes from patients with myeloproliferative neoplasms. Blood, 2020, 135, 133-144.	0.6	52
182	THE TRIPLICATED ALPHA-GENE LOCUS AND HETEROZYGOUS BETA THALASSAEMIA: A CASE OF THALASSAEMIA INTERMEDIA. British Journal of Haematology, 1983, 55, 709-710.	1.2	51
183	Soluble transferrin receptor as a potential determinant of iron loading in congenital anaemias due to ineffective erythropoiesis. British Journal of Haematology, 1999, 106, 752-755.	1.2	51
184	Inappropriately low hepcidin levels in patients with myelodysplastic syndrome carrying a somatic mutation of SF3B1. Haematologica, 2013, 98, 420-423.	1.7	51
185	Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene. Annals of Hematology, 2015, 94, 1927-1928.	0.8	51
186	Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System. Leukemia, 2017, 31, 2449-2457.	3.3	51
187	Combined Cohesinâ€“RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes. Cancer Discovery, 2020, 10, 836-853.	7.7	51
188	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 4		51
189	Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. American Journal of Hematology, 2014, 89, 306-309.	2.0	50
190	Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. British Journal of Haematology, 1983, 54, 649-654.	1.2	50
191	Myelodysplastic/Myeloproliferative Neoplasms. Hematology American Society of Hematology Education Program, 2011, 2011, 264-272.	0.9	49
192	Germline RBBP6 mutations in familial myeloproliferative neoplasms. Blood, 2016, 127, 362-365.	0.6	49
193	Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood, 1996, 87, 4824-30.	0.6	48
194	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated With a PCM1-JAK2 Fusion Gene. Journal of Clinical Oncology, 2013, 31, e269-e271.	0.8	47
195	Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 1107-1110.	2.0	47
196	A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. British Journal of Haematology, 2014, 167, 541-546.	1.2	47
197	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	2.0	47
198	Recombinant human erythropoietin in the anemia associated with multiple myeloma or non-Hodgkin's lymphoma: dose finding and identification of predictors of response. Blood, 1995, 86, 4446-53.	0.6	47

#	Article	IF	Citations
199	Pseudouridine-modified tRNA fragments repress aberrant protein synthesis and predict leukaemic progression in myelodysplastic syndrome. Nature Cell Biology, 2022, 24, 299-306.	4.6	47
200	Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes. Blood, 2016, 128, 2096-2097.	0.6	46
201	Immunophenotypic, cytogenetic and functional characterization of circulating endothelial cells in myelodysplastic syndromes. Leukemia, 2008, 22, 530-537.	3.3	45
202	Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia, 2012, 26, 1439-1441.	3.3	45
203	Identification of Gene Expressionâ€“Based Prognostic Markers in the Hematopoietic Stem Cells of Patients With Myelodysplastic Syndromes. Journal of Clinical Oncology, 2013, 31, 3557-3564.	0.8	45
204	The effect of arterial hypertension on thrombosis in lowâ€risk polycythemia vera. American Journal of Hematology, 2017, 92, E5-E6.	2.0	45
205	Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget, 2017, 8, 101735-101744.	0.8	45
206	Estimation of Ferrokinetic Parameters by a Mathematical Model in Patients with Primary Acquired Sideroblastic Anaemia. British Journal of Haematology, 1978, 39, 409-423.	1.2	44
207	Myeloproliferative neoplasms: From JAK2 mutations discovery to JAK2 inhibitor therapies. Oncotarget, 2011, 2, 485-490.	0.8	44
208	Circulating thrombopoietin in reactive conditions behaves like an acute phase reactant. International Journal of Laboratory Hematology, 1999, 21, 271-275.	0.2	42
209	Erythropoiesis in Myelofibrosis with Myeloid Metaplasia: Recognition of Different Classes of Patients by Erythrokinetics. British Journal of Haematology, 1981, 48, 263-272.	1.2	42
210	Molecular basis of myelodysplastic/myeloproliferative neoplasms. Haematologica, 2009, 94, 1634-1638.	1.7	41
211	Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages. Journal of Immunology, 2017, 199, 1516-1525.	0.4	41
212	Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms. American Journal of Hematology, 2017, 92, 187-195.	2.0	41
213	Driver mutationsâ€™ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia, 2017, 31, 970-973.	3.3	41
214	JAK2 (V617F) mutation in healthy individuals. British Journal of Haematology, 2007, 136, 678-679.	1.2	40
215	Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes. Hematology/Oncology Clinics of North America, 2010, 24, 459-468.	0.9	39
216	Microelectronic DNA chip for hereditary hyperferritinemia cataract syndrome, a model for large-scale analysis of disorders of iron metabolism. Human Mutation, 2006, 27, 201-208.	1.1	38

#	Article	IF	Citations
217	Manipulations of cellular iron metabolism for modulating normal and malignant cell proliferation: achievements and prospects. Blood, 1990, 75, 1903-19.	0.6	38
218	Role of ferritin and ferroportin genes in unexplained hyperferritinaemia. Best Practice and Research in Clinical Haematology, 2005, 18, 251-263.	0.7	37
219	Identification of genomic aberrations associated with disease transformation by means of highâ€resolution SNP array analysis in patients with myeloproliferative neoplasm. American Journal of Hematology, 2011, 86, 974-979.	2.0	37
220	Refractory anemia with ring sideroblasts. Best Practice and Research in Clinical Haematology, 2013, 26, 377-385.	0.7	37
221	Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis. British Journal of Haematology, 2002, 116, 855-861.	1.2	36
222	Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders. British Journal of Haematology, 2004, 126, 650-656.	1.2	36
223	Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. Journal of Thrombosis and Haemostasis, 2010, 8, 411-413.	1.9	36
224	LNK mutations in familial myeloproliferative neoplasms. Blood, 2016, 128, 144-145.	0.6	36
225	Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia. American Journal of Hematology, 2006, 81, 124-127.	2.0	35
226	Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis. Blood Cancer Journal, 2020, 10, 21.	2.8	35
227	Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial [see comments]. Blood, 1992, 79, 29-37.	0.6	35
228	A patient-oriented approach to treatment of myelodysplastic syndromes. Haematologica, 1998, 83, 910-35.	1.7	35
229	The possible role of burden of therapy on the risk of myeloma extramedullary spread. Annals of Hematology, 2017, 96, 73-80.	0.8	34
230	Novel drivers and modifiers of MPL-dependent oncogenic transformation identified by deep mutational scanning. Blood, 2020, 135, 287-292.	0.6	34
231	An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression. Cancer, 1991, 68, 2310-2318.	2.0	33
232	Oligodeoxynucleotides antisense to c-abl specifically inhibit entry into S-phase of CD34+ hematopoietic cells and their differentiation to granulocyte-macrophage progenitors. Blood, 1995, 86, 3387-3393.	0.6	33
233	Advances in understanding the pathogenesis of familial myeloproliferative neoplasms. British Journal of Haematology, 2017, 178, 689-698.	1.2	33
234	Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. Haematologica, 2003, 88, 1123-9.	1.7	33

#	Article	IF	Citations
235	Scanning mutations of the 5â€²UTR regulatory sequence of l -ferritin by denaturing high-performance liquid chromatography: identification of new mutations. British Journal of Haematology, 2003, 121, 173-179.	1.2	32
236	The Role of JAK2 Mutations in RARS and Other MDS. Hematology American Society of Hematology Education Program, 2008, 2008, 52-59.	0.9	32
237	Diagnosis and treatment of sideroblastic anemias: from defective heme synthesis to abnormal RNA splicing. Hematology American Society of Hematology Education Program, 2015, 2015, 19-25.	0.9	32
238	Secreted Mutant Calreticulins As Rogue Cytokines Trigger Thrombopoietin Receptor Activation Specifically in CALR Mutated Cells: Perspectives for MPN Therapy. Blood, 2018, 132, 4-4.	0.6	32
239	Gene expression profiling of erythroblasts from refractory anaemia with ring sideroblasts (RARS) and effects of Gâ€CSF. British Journal of Haematology, 2010, 149, 844-854.	1.2	31
240	correspondence: Incidence of leukaemia in patients with primary myelofibrosis and RBCâ€“transfusionâ€dependence. British Journal of Haematology, 2010, 150, 719-721.	1.2	31
241	A novel germline JAK2 mutation in familial myeloproliferative neoplasms. American Journal of Hematology, 2014, 89, 117-118.	2.0	31
242	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica, 2018, 103, e392-e394.	1.7	31
243	Effect of acidic and basic isoferritins on in vitro growth of human granulocyte-monocyte progenitors. Blood, 1986, 67, 789-795.	0.6	30
244	Characteristics of a ferritinâ€binding protein present in human serum. British Journal of Haematology, 1987, 65, 489-493.	1.2	30
245	Juvenile Genetic Hemochromatosis Is Clinically and Genetically Distinct From the Classical HLA-Related Disorder. Blood, 1998, 92, 2979-2981.	0.6	30
246	Increase in leukocyte count over time predicts thrombosis in patients with lowâ€risk essential thrombocythemia. Journal of Thrombosis and Haemostasis, 2009, 7, 1587-1589.	1.9	30
247	Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica, 2015, 100, e443-e445.	1.7	30
248	MYD88 mutated and wild-type WaldenstrÃ¶mâ€™s Macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4. Haematologica, 2018, 103, e408-e411.	1.7	30
249	Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach. American Journal of Hematology, 2022, 97, 514-518.	2.0	30
250	Killing of K562 cells with conjugates between human transferrin and a ribosome-inactivating protein (SO-6). British Journal of Haematology, 1988, 68, 379-384.	1.2	29
251	The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy. Haematologica, 2021, 106, 3004-3007.	1.7	29
252	A Phase 2 Study of INCB018424, An Oral, Selective JAK1/JAK2 Inhibitor, in Patients with Advanced Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Refractory to Hydroxyurea.. Blood, 2009, 114, 311-311.	0.6	29

#	Article	IF	Citations
253	RED CELL FERRITIN AS A DIAGNOSTIC TOOL. British Journal of Haematology, 1986, 62, 209-213.	1.2	28
254	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Phâ€negative peripheral stem cells. British Journal of Haematology, 1994, 87, 867-870.	1.2	28
255	Immunocytochemical detection of ferritin in human bone marrow and peripheral blood cells using monoclonal antibodies specific for the H and L subunit. British Journal of Haematology, 1990, 76, 427-432.	1.2	27
256	Ferroportin gene silencing induces iron retention and enhances ferritin synthesis in human macrophages. British Journal of Haematology, 2004, 127, 598-603.	1.2	27
257	CALR mutational status identifies different disease subtypes of essential thrombocythemia showing distinct expression profiles. Blood Cancer Journal, 2017, 7, 638.	2.8	27
258	Infection perturbs Bach2- and Bach1-dependent erythroid lineage â€˜choiceâ€™ to cause anemia. Nature Immunology, 2018, 19, 1059-1070.	7.0	27
259	A PROGNOSTIC MODEL to PREDICT SURVIVAL In WHO-DEFINED ESSENTIAL THROMBOCYTHEMIA: A STUDY by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf		27
260	Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood, 2000, 96, 4363-5.	0.6	27
261	A novel deletion of the l -ferritin iron-responsive element responsible for severe hereditary hyperferritinaemia-cataract syndrome. British Journal of Haematology, 2002, 116, 667-670.	1.2	26
262	Myelodysplastic/myeloproliferative disorders. Haematologica, 2008, 93, 4-6.	1.7	26
263	Myelodysplastic syndrome with isolated 5q deletion (5q- syndrome). A clonal stem cell disorder characterized by defective ribosome biogenesis. Haematologica, 2008, 93, 967-972.	1.7	26
264	Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. Journal of Internal Medicine, 2009, 265, 266-274.	2.7	26
265	Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. Blood Cancer Journal, 2018, 8, 25.	2.8	26
266	Ruxolitinib treatment and risk of Bâ€cell lymphomas in myeloproliferative neoplasms. American Journal of Hematology, 2019, 94, E185-E188.	2.0	26
267	Studies of Ineffective Erythropoiesis and Peripheral Haemolysis in Congenital Dyserythropoietic Anaemia Type II. British Journal of Haematology, 1979, 43, 243-250.	1.2	25
268	Marked downregulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. British Journal of Haematology, 2009, 146, 86-90.	1.2	25
269	Recent advances in the understanding of myelodysplastic syndromes with ring sideroblasts. British Journal of Haematology, 2016, 174, 847-858.	1.2	25
270	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.4	25

#	Article	IF	Citations
271	Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. Annals of Hematology, 2004, 83, 495-7.	0.8	24
272	Monoclonal gammopathy of undetermined significance: a new proposal of workup. European Journal of Haematology, 2013, 91, 356-360.	1.1	24
273	Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and Â-thalassemia intermedia. Haematologica, 2015, 100, e169-e171.	1.7	24
274	Immunological Reactivity of Serum Ferritin in Patients with Malignancy. Tumori, 1985, 71, 547-554.	0.6	23
275	Absent phenotypic expression of X-linked sideroblastic anemia in one of 2 brothers with a novel ALAS2 mutation. Blood, 2002, 100, 4236-4238.	0.6	23
276	IDH1 and IDH2 mutations in myeloid neoplasms - Novel paradigms and clinical implications. Haematologica, 2010, 95, 1623-1627.	1.7	23
277	14 Revised International Prognostic Scoring System (IPSS-R), developed by the International Prognostic Working Group for Prognosis in MDS (IWG-PM). Leukemia Research, 2011, 35, S6.	0.4	23
278	Independent prognostic impact of tumour-infiltrating macrophages in early-stage Hodgkin's lymphoma. Hematological Oncology, 2017, 35, 296-302.	0.8	23
279	Ineffective erythropoiesis and its treatment. Blood, 2022, 139, 2460-2470.	0.6	23
280	Pregnancy outcome and management of 25 pregnancies in women with polycythemia vera. American Journal of Hematology, 2018, 93, E234-E235.	2.0	22
281	Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. Blood, 1992, 79, 29-37.	0.6	22
282	Myelodysplastic syndromes: recent advances. Haematologica, 2001, 86, 1124-57.	1.7	22
283	Quantitative Evaluation of the Mechanisms of the Anaemia in Heterozygous Î²â€Thalassaemia. Scandinavian Journal of Haematology, 1979, 23, 107-114.	0.0	21
284	Gain of function, loss of control - a molecular basis for chronic myeloproliferative disorders. Haematologica, 2005, 90, 871-4.	1.7	21
285	Erythropoiesis in Myelofibrosis with Myeloid Metaplasia: Recognition of Different Classes of Patients by Erythrokinetics. British Journal of Haematology, 1981, 48, 263-272.	1.2	20
286	Refractory cytopenias: Clinical course according to bone marrow cytology and cellularity. Blut, 1987, 54, 153-163.	1.2	20
287	Ferrokinetic Measurement of Erythropoiesis. Acta Haematologica, 1988, 79, 121-126.	0.7	20
288	Risk assessment in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2011, 96, 349-352.	1.7	20

#	Article	IF	Citations
289	Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms. British Journal of Cancer, 2017, 116, 335-343.	2.9	20
290	Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS. Leukemia Research, 2018, 73, 51-57.	0.4	20
291	Red Blood Cell Precursor Mass as an Independent Determinant of Serum Erythropoietin Level. Blood, 1998, 91, 2139-2145.	0.6	20
292	Four new mutations in the erythroid-specific 5-aminolevulinate synthase (ALAS2) gene causing X-linked sideroblastic anemia: increased pyridoxine responsiveness after removal of iron overload by phlebotomy and coinheritance of hereditary hemochromatosis. Blood, 1999, 93, 1757-69.	0.6	20
293	Use of a monoclonal antibody against human heart ferritin for evaluating acidic ferritin concentration in human serum. British Journal of Haematology, 1985, 61, 445-453.	1.2	19
294	Exclusion of ZIRTL as Candidate Gene of Juvenile Hemochromatosis and Refinement of the Critical Interval on 1q21. Blood Cells, Molecules, and Diseases, 2000, 26, 205-210.	0.6	19
295	Somatic mutations of JAK2 exon 12 as a molecular basis of erythrocytosis. Haematologica, 2007, 92, 1585-1589.	1.7	19
296	Prognostic Impact of Mutations in a Large Series of Patients with Myelofibrosis. Blood, 2012, 120, 431-431.	0.6	19
297	Ferritin in the red cells of normal subjects and patients with iron deficiency and iron overload. British Journal of Haematology, 1983, 53, 659-665.	1.2	18
298	A WHO Classification-Based Prognostic Scoring System (WPSS) for Predicting Survival in Myelodysplastic Syndromes.. Blood, 2005, 106, 788-788.	0.6	18
299	Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation. British Journal of Haematology, 1993, 84, 752-754.	1.2	17
300	A model for analysing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplantation, 1999, 23, 719-725.	1.3	17
301	Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2P95-mutated neoplasms. Leukemia, 2021, 35, 2371-2381.	3.3	17
302	Natural history of idiopathic refractory sideroblastic anemia. Blood, 1988, 71, 305-12.	0.6	17
303	Basic and acidic isoferritins in the serum of patients with Hodgkin's disease. European Journal of Cancer & Clinical Oncology, 1983, 19, 339-345.	0.9	16
304	Prognostic significance of reproducible immunophenotypic markers of marrow dysplasia. Haematologica, 2014, 99, e8-e10.	1.7	16
305	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. Cancer Medicine, 2019, 8, 4089-4092.	1.3	16
306	A Decision Analysis of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation for Older Patients with De-Novo Myelodysplastic Syndrome (MDS): Early Transplantation Offers Survival Benefit in Higher-Risk MDS. Blood, 2011, 118, 115-115.	0.6	16

#	Article	IF	Citations
307	Effects of recombinant human H-subunit and L-subunit ferritins on in vitro growth of human granulocyteâ€"monocyte progenitors. British Journal of Haematology, 1988, 68, 367-372.	1.2	15
308	Distinct Genetic Lesions Drive Leukemogenesis in Secondary Acute Myeloid Leukemia,. Blood, 2011, 118, 3559-3559.	0.6	15
309	Denaturing HPLC analysis of DNA deletions and insertions. Human Mutation, 2003, 22, 98-102.	1.1	14
310	Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Haematologica, 2014, 99, 1650-1652.	1.7	14
311	Long-Term Results from a Phase II Open-Label Study of Ruxolitinib in Patients with Essential Thrombocythemia Refractory to or Intolerant of Hydroxyurea. Blood, 2014, 124, 1847-1847.	0.6	14
312	Adequacy of iron supply for erythropoiesis: in vivo observations in humans. Translational Research, 1987, 110, 734-9.	2.4	14
313	Quantitative Assessment of Erythropoiesis in Haemolytic Disease. British Journal of Haematology, 1980, 45, 297-308.	1.2	13
314	Classification of anaemia on the basis of ferrokinetic parameters. British Journal of Haematology, 1985, 61, 357-370.	1.2	13
315	Antibodies for denatured human H-ferritin stain only reticuloendothelial cells within the bone marrow. British Journal of Haematology, 1992, 81, 118-124.	1.2	13
316	Disease anticipation in familial myeloproliferative neoplasms. Blood, 2008, 112, 2587-2588.	0.6	13
317	Polycythaemia Following Splenectomy in Myelofibrosis with Myeloid Metaplasia. A Reorganization of Erythropoiesis. Scandinavian Journal of Haematology, 1984, 32, 12-18.	0.0	13
318	Prognostic parameters in myelodysplastic syndromes: A multiple regression analysis. European Journal of Haematology, 1988, 40, 158-162.	1.1	13
319	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer Journal, 2018, 8, 89.	2.8	13
320	Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes. American Journal of Hematology, 2020, 95, 133-143.	2.0	13
321	RNAmut: robust identification of somatic mutations in acute myeloid leukemia using RNA-sequencing. Haematologica, 2020, 105, e290-e293.	1.7	13
322	An improved method for liquid scintillation counting of 59Fe in ferrokinetic studies. Haematologica, 1974, 59, 54-67.	1.7	13
323	Pure red cell aplasia following peripheral stem cell transplantation: complete response to a short course of high-dose recombinant human erythropoietin. Haematologica, 1994, 79, 456-9.	1.7	13
324	Recombinant human erythropoietin is effective in correcting erythropoietinâ€deficient anaemia after allogeneic bone marrow transplantation. British Journal of Haematology, 1992, 80, 545-549.	1.2	12

#	Article	IF	Citations
325	Pulmonary Penetration of Ceftazidime. Journal of Chemotherapy, 1995, 7, 50-54.	0.7	12
326	Both cycling and noncycling primitive progenitors continue to be mobilized into the circulation during the leukapheresis of patients pretreated with chemotherapy and G-CSF. British Journal of Haematology, 1997, 99, 394-402.	1.2	12
327	Molecular basis of thrombocytosis. Haematologica, 2008, 93, 646-648.	1.7	12
328	Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphaseâ€FISH. Hematological Oncology, 2013, 31, 136-142.	0.8	12
329	Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation. Blood, 2019, 133, 2802-2808.	0.6	12
330	Treatment with Erythropoietin and G-CSF Improves Survival in MDS Patients with Low Transfusion Need.. Blood, 2006, 108, 521-521.	0.6	12
331	A simple method for simultaneous liquid scintillation counting of 59Fe and 51Cr in blood. The International Journal of Applied Radiation and Isotopes, 1976, 27, 660-662.	0.7	11
332	Red cell aplasia in myelofibrosis with myeloid metaplasia. A distinct functional and clinical entity. Cancer, 1983, 52, 1290-1296.	2.0	11
333	Establishment and characterization of a B-cell line derived from a patient with a myelodysplastic syndrome which expresses myelomonocytic and lymphoid markers. British Journal of Haematology, 1991, 78, 167-172.	1.2	11
334	Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. British Journal of Haematology, 1999, 104, 538-545.	1.2	11
335	Cell cycle distribution of cord blood-derived haematopoietic progenitor cells and their recruitment into the S-phase of the cell cycle. British Journal of Haematology, 2000, 108, 621-628.	1.2	11
336	Mutant calreticulin: when a chaperone becomes intrusive. Blood, 2016, 127, 1219-1221.	0.6	11
337	Clonal monocytosis of clinical significance. Blood, 2019, 133, 1271-1272.	0.6	11
338	Developing a classification of hematologic neoplasms in the era of precision medicine. Blood, 2022, 140, 1193-1199.	0.6	11
339	Effects of mitochondrial ferritin overexpression in normal and sideroblastic erythroid progenitors. British Journal of Haematology, 2013, 161, 726-737.	1.2	10
340	Myelodysplastic syndromes: biologic and clinical aspects. Haematologica, 1986, 71, 147-59.	1.7	10
341	Evaluation of erythroid marrow function in anemic patients. Haematologica, 1987, 72, 195-200.	1.7	10
342	Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood, 1998, 91, 2139-45.	0.6	10

#	Article	IF	Citations
343	Cell kinetics of CD34-positive hematopoietic cells following chemotherapy plus colony-stimulating factors in advanced breast cancer. International Journal of Cancer, 1995, 63, 646-651.	2.3	9
344	Hereditary hyperferritinaemia/ cataract syndrome. Best Practice and Research in Clinical Haematology, 2002, 15, 385-398.	0.7	9
345	Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. Bone Marrow Transplantation, 2010, 45, 798-800.	1.3	9
346	COLD-PCR and Innovative Microarray Substrates for Detecting and Genotyping MPL Exon 10 W515 Substitutions. Clinical Chemistry, 2012, 58, 1692-1702.	1.5	9
347	Bone marrow assessment in asymptomatic immunoglobulin <scp>M</scp> monoclonal gammopathies. British Journal of Haematology, 2015, 168, 301-302.	1.2	9
348	Benefits and risks of JAK inhibition. Blood, 2018, 132, 675-676.	0.6	9
349	Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide. Leukemia, 2021, 35, 1197-1202.	3.3	9
350	Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. PLoS ONE, 2013, 8, e77819.	1.1	9
351	Loss of Heterozygosity on Chromosome 9p24 Is the Most Frequent Chromosomal Aberration in Polycythemia Vera and Idiopathic Myelofibrosis.. Blood, 2004, 104, 2425-2425.	0.6	9
352	Recombinant gamma-interferon induces in vitro monocytic differentiation of blast cells from patients with acute nonlymphocytic leukemia and myelodysplastic syndromes. Leukemia, 1988, 2, 55-9.	3.3	9
353	Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin-3 on Small Cell Lung Cancer Cells. Cancer Investigation, 1994, 12, 283-288.	0.6	8
354	Expression of adhesion molecules and functional stimulation in human neutrophils: modulation by GMâ€CSF and role of the Bcr gene. British Journal of Haematology, 1997, 98, 621-626.	1.2	8
355	Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment. Blood, 1998, 91, 360-362.	0.6	8
356	PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia. Leukemia, 2005, 19, 888-889.	3.3	8
357	Iron Kinetics and Erythropoiesis in Fanconi's Anaemia. Scandinavian Journal of Haematology, 1978, 21, 29-39.	0.0	8
358	Blast phase of essential thrombocythemia: A single center study. American Journal of Hematology, 2009, 84, 641-644.	2.0	8
359	Responseâ€adjusted ISS (RaISS) is a simple and reliable prognostic scoring system for predicting progressionâ€free survival in transplanted patients with multiple myeloma. American Journal of Hematology, 2012, 87, 150-154.	2.0	8
360	Impact of bone marrow fibrosis grade in postâ€polycythemia vera and postâ€essential thrombocythemia myelofibrosis: A study of the MYSEC group. American Journal of Hematology, 2020, 95, E1-E3.	2.0	8

#	Article	IF	Citations
361	Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis. Blood Advances, 2021, 5, 1452-1462.	2.5	8
362	Myelodysplastic Syndrome (MDS)-Specific Comorbidity Index for Predicting the Impact of Extra-Hematological Comorbidities on Survival of Patients with MDS. Blood, 2008, 112, 2677-2677.	0.6	8
363	Comparison of Outcomes of Advanced Myelofibrosis Patients Treated with Ruxolitinib (INCB018424) to Those of a Historical Control Group: Survival Advantage of Ruxolitinib Therapy. Blood, 2011, 118, 793-793.	0.6	8
364	<scp>PDâ€Ł1</scp> overexpression correlates with <scp>JAK2â€V617F</scp> mutational burden and is associated with 9p uniparental disomy in myeloproliferative neoplasms. American Journal of Hematology, 2022, 97, 390-400.	2.0	8
365	Evaluation of lung tissue and hilar lymph node concentrations of azithromycin. International Journal of Clinical Pharmacology and Therapeutics, 1994, 32, 88-91.	0.3	8
366	A screen for RAS mutations in individuals at risk of secondary leukaemia due to occupational exposure to petrochemicals. Leukemia Research, 1995, 19, 299-301.	0.4	7
367	Cold Haemagglutinin Disease with Severe Anaemia, Reticulocytopenia and Erythroid Bone Marrow. Scandinavian Journal of Haematology, 1983, 30, 25-29.	0.0	7
368	Good clinical activity and favorable toxicity profile of once weekly bortezomib, fotemustine, and dexamethasone (Bâ€MuD) for the treatment of relapsed multiple myeloma. American Journal of Hematology, 2013, 88, 102-106.	2.0	7
369	Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2019, 134, 841-841.	0.6	7
370	Clinical Impacts of Germline DDX41 Mutations on Myeloid Neoplasms. Blood, 2020, 136, 38-40.	0.6	7
371	Mitochondrial Ferritin Expression and Clonality of Hematopoiesis in Patients with Refractory Anemia with Ringed Sideroblasts.. Blood, 2005, 106, 3444-3444.	0.6	7
372	Erythroid Activity, Transfusion Iron Overload, and Hepcidin Levels in Patients with Myelodysplastic Syndrome. Blood, 2008, 112, 2676-2676.	0.6	7
373	Deletions of the Transcription Factor Ikaros in Myeloproliferative Neoplasms at Transformation to Acute Myeloid Leukemia.. Blood, 2009, 114, 435-435.	0.6	7
374	Survival and Prognosis Among 1,263 Patients with Polycythemia Vera: An International Study. Blood, 2011, 118, 277-277.	0.6	7
375	Gene Mutations and Treatment Outcome in Chronic Lymphocytic Leukemia: Results From the CLL8 Trial. Blood, 2012, 120, 433-433.	0.6	7
376	Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms. Oncotarget, 2017, 8, 33416-33421.	0.8	7
377	Patient-specific MDS-RS iPSCs define the mis-spliced transcript repertoire and chromatin landscape of SF3B1-mutant HSPCs. Blood Advances, 2022, 6, 2992-3005.	2.5	7
378	Guidelines for the use of recombinant human erythropoietin. Haematologica, 1994, 79, 526-33.	1.7	7

#	Article	IF	Citations
379	Erythropoietin therapy: need for rationality and active surveillance. Haematologica, 2003, 88, 601-5.	1.7	7
380	Not just clonal expansion of hematopoietic cells, but also activation of their progeny in the pathogenesis of myeloproliferative disorders. Haematologica, 2006, 91, 159.	1.7	7
381	Validation of cytogenetic-based risk stratification in primary myelofibrosis. Blood, 2010, 115, 2719-2720.	0.6	6
382	Marked downâ€regulation of nucleophosminâ€1 is associated with advanced del(5q) myelodysplastic syndrome. British Journal of Haematology, 2011, 155, 272-274.	1.2	6
383	The relevance of transfusionâ€dependency in the prognostic assessment of patients with myeloid neoplasms. American Journal of Hematology, 2011, 86, 241-243.	2.0	6
384	Integrative analysis of copy number and gene expression data suggests novel pathogenetic mechanisms in primary myelofibrosis. International Journal of Cancer, 2016, 138, 1657-1669.	2.3	6
385	TP53 Mutation Status Divides MDS Patients with Complex Karyotypes into Distinct Prognostic Risk Groups: Analysis of Combined Datasets from the International Working Group for MDS-Molecular Prognosis Committee. Blood, 2014, 124, 532-532.	0.6	6
386	Comprehensive Analysis of Aberrant RNA Splicing in Myelodysplastic Syndromes. Blood, 2014, 124, 826-826.	0.6	6
387	Four New Mutations in the Erythroid-Specific 5-Aminolevulinate Synthase (ALAS2) Gene Causing X-Linked Sideroblastic Anemia: Increased Pyridoxine Responsiveness After Removal of Iron Overload by Phlebotomy and Coinheritance of Hereditary Hemochromatosis. Blood, 1999, 93, 1757-1769.	0.6	6
388	Translational pathophysiology: a novel molecular mechanism of human disease. Blood, 2000, 95, 3280-3288.	0.6	6
389	Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia. Blood, 2014, 124, 1915-1915.	0.6	6
390	X-linked chronic granulomatous disease in an adult woman. Evidence for a cell selection favoring neutrophils expressing the mutant allele. Haematologica, 1985, 70, 291-5.	1.7	6
391	Measurement of Ferritin-Bearing Lymphocytes in Man. Preliminary Studies on the Use of Monoclonal Antibodies Specific for the L and H Subunits of Ferritin. Tumori, 1987, 73, 37-41.	0.6	5
392	Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. Experimental Hematology, 2000, 28, 210-215.	0.2	5
393	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. Leukemia and Lymphoma, 2007, 48, 805-807.	0.6	5
394	Flow cytometry immunophenotyping for diagnosis of myelodysplastic syndrome. Haematologica, 2009, 94, 1041-1043.	1.7	5
395	Allelic imbalance in CALR somatic mutagenesis. Leukemia, 2015, 29, 1431-1435.	3.3	5
396	Introduction to a review series on iron metabolism and its disorders. Blood, 2019, 133, 1-2.	0.6	5

#	Article	IF	Citations
397	A continuous-time Markov model approach for modeling myelodysplastic syndromes progression from cross-sectional data. Journal of Biomedical Informatics, 2020, 104, 103398.	2.5	5
398	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib.. Blood, 2004, 104, 1504-1504.	0.6	5
399	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	0.6	5
400	Hereditary Hyperferritinemia-Cataract Syndrome: Relationship Between Phenotypes and Specific Mutations in the Iron-Responsive Element of Ferritin Light-Chain mRNA. Blood, 1997, 90, 814-821.	0.6	5
401	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	0.6	5
402	Evidence for the existence of two populations of erythroid cells in a case of congenital dyserythropoietic anaemia type II. Haematologica, 1982, 67, 508-16.	1.7	5
403	Juvenile genetic hemochromatosis is clinically and genetically distinct from the classical HLA-related disorder. Blood, 1998, 92, 2979-81.	0.6	5
404	Transferrin saturation, plasma iron turnover, and transferrin uptake in normal humans. Blood, 1985, 66, 935-939.	0.6	5
405	Abnormal splenic uptake of red cells in long-lasting iron deficiency anemia due to self-induced bleeding (factitious anemia). Blut, 1978, 37, 75-82.	1.2	4
406	Prognostic relevance of anemia in myelodysplastic syndromes. American Journal of Hematology, 2008, 83, 761-762.	2.0	4
407	Competing Models for the Analysis of Red Cell Survival Obtained with ⁵¹Cr Labelling Technique. Scandinavian Journal of Haematology, 1983, 31, 381-388.	0.0	4
408	Pathophysiological classification of acquired bone marrow failure based on quantitative assessment of erythroid function. European Journal of Haematology, 1987, 38, 426-432.	1.1	4
409	Detection of TET2 abnormalities by fluorescence in situ hybridization in 41 patients with myelodysplastic syndrome. Cancer Genetics, 2012, 205, 285-294.	0.2	4
410	The <scp>ERCC2 G</scp>ln/<scp>G</scp>ln polymorphism at codon 751 is not associated with leukaemic transformation in primary myelofibrosis. British Journal of Haematology, 2013, 162, 424-427.	1.2	4
411	Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. Annals of Hematology, 2014, 93, 523-524.	0.8	4
412	Impaired virusâ€specific T cell responses in patients with myeloproliferative neoplasms treated with ruxolitinib. Hematological Oncology, 2020, 38, 554-559.	0.8	4
413	A Prognostic Model for Predicting the Impact of Comorbidities on Survival of Patients with Myelodysplastic Syndromes.. Blood, 2007, 110, 2453-2453.	0.6	4
414	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). Blood, 2014, 124, 1826-1826.	0.6	4

#	Article	IF	Citations
415	Towards a Better Understanding of Epidemiology, Survival and Treatment in Myeloproliferative Neoplasms: Results of the European Leukemianet Registry (ERNEST study). Blood, 2014, 124, 1849-1849.	0.6	4
416	SF3B1 Mutation Is an Independent Predictor of Parenchymal Iron Overload in Myelodysplastic Syndromes. Blood, 2015, 126, 1678-1678.	0.6	4
417	The use of 59Fe for estimating red cell production and destruction: a comparative evaluation of two methods for the analysis of experimental data. Haematologica, 1979, 64, 696-713.	1.7	4
418	The origin of serum ferritin in acquired transfusional iron overload in adults. Studies with concanavalin A-sepharose absorption. Haematologica, 1982, 67, 817-24.	1.7	4
419	ERYTHROPOIESIS AND IRON KINETICS. British Journal of Haematology, 1978, 40, 503-504.	1.2	3
420	Erythropoietin pathophysiology and erythropoietin deficiency anemia. The Hematology Journal, 2004, 5, S100-S103.	2.0	3
421	Iron loading in congenital dyserythropoietic anaemias and congenital sideroblastic anaemias. British Journal of Haematology, 2008, 54, 649-654.	1.2	3
422	Erythropoiesis in Hairy Cell Leukaemia: A True Erythroid Failure. Scandinavian Journal of Haematology, 1982, 28, 97-102.	0.0	3
423	Molecular basis of congenital dyserythropoietic anemia type II and genotype-phenotype relationship. Haematologica, 2010, 95, 693-695.	1.7	3
424	Vascular endothelial growth factor overexpression in myelodysplastic syndrome bone marrow cells: biological and clinical implications. Leukemia and Lymphoma, 2017, 58, 1711-1720.	0.6	3
425	Abstract 5552: Extremely high rate of complete hematological response of elderly Ph+ acute lymphoblastic leukemia (ALL) patients by innovative sequential use of Nilotinib and Imatinib. A GIMEMA Protocol LAL 1408. , 2014, , .		3
426	Mutational Landscape of the Transcriptome Offers a Rich Neoantigen Resource for Immunotherapy of Myeloproliferative Neoplasms. Blood, 2018, 132, 3058-3058.	0.6	3
427	Molecular and Clinical Features of the Myeloproliferative Neoplasm Associated with JAK2 Exon 12 Mutations: a European Multicenter Study.. Blood, 2009, 114, 3904-3904.	0.6	3
428	Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. Blood, 2011, 118, 3-3.	0.6	3
429	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	0.6	3
430	Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia. Blood, 1987, 70, 1014-1019.	0.6	3
431	Chromosomal Aberration Network In Myeloproliferative Neoplasms. Blood, 2010, 116, 318-318.	0.6	3
432	An approach by means of mathematical models to the analysis of ferrokinetic data obtained by liquid scintillation counting of 59Fe. Journal of Long Island History, 1976, 20, 8-22.	0.1	3

#	Article	IF	Citations
433	Erythrophagocytosis increases the expression of erythroid potentiating activity mRNA in human monocyte-macrophages. Experimental Hematology, 1993, 21, 70-3.	0.2	3
434	IRON LOADING IN Î²-THALASSÃ†MIA. Lancet, The, 1980, 315, 204.	6.3	2
435	Ring sideroblasts and myelodysplastic syndromes.. Journal of Clinical Pathology, 1983, 36, 1413-1414.	1.0	2
436	Proliferation kinetics of bone marrow cells in congenital dyserythropoietic anemia type II. Blut, 1985, 50, 219-224.	1.2	2
437	Juvenile chronic myelogenous leukemia: In vitro characterization before and after allogeneic bone marrow transplantation. Medical and Pediatric Oncology, 1995, 24, 166-170.	1.0	2
438	Can EPO reduce blood transfusion requirements during induction therapy for high-risk neuroblastoma?. Nature Clinical Practice Oncology, 2004, 1, 22-23.	4.3	2
439	Similar neurotoxicity of an alternating compared to a continuous low-dose schedule of thalidomide for relapsed/refractory multiple myeloma. Leukemia and Lymphoma, 2012, 53, 514-515.	0.6	2
440	Serum C terminal telopeptide maintains its correlation with bone disease in patients with myeloma even under treatment with bisphosphonates. Leukemia and Lymphoma, 2014, 55, 1397-1398.	0.6	2
441	Corneal sub-basal neural damage pattern in multiple myeloma patients treated with bortezomib: anin vivoconfocal study. Leukemia and Lymphoma, 2015, 56, 3440-3441.	0.6	2
442	Molecular remission at the end of treatment is a necessary goal for a good outcome in ELN favorable-risk acute myeloid leukemia: a real-life analysis on 201 patients by the Rete Ematologica Lombarda network. Annals of Hematology, 2018, 97, 2107-2115.	0.8	2
443	Introduction to a review series on inherited anemias. Blood, 2020, 136, 1215-1216.	0.6	2
444	The Effect of Transfusion Dependency and Secondary Iron Overload on Survival of Patients with Myelodysplastic Syndrome.. Blood, 2005, 106, 791-791.	0.6	2
445	Mutation Analysis of TET2 Reveals the Clonal Nature of Refractory Anemia with Ring Sideroblasts. Blood, 2010, 116, 1862-1862.	0.6	2
446	Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes. Blood, 2015, 126, 139-139.	0.6	2
447	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	0.6	2
448	Predictive Value of Mutation Analysis in the Diagnostic Approach to Patients with Unexplained Cytopenia. Blood, 2016, 128, 298-298.	0.6	2
449	Erythroid marrow function in anemic patients. Blood, 1987, 69, 296-301.	0.6	2
450	Towards a rational treatment of essential thrombocythemia, despite limited evidence and old prejudices. Haematologica, 2004, 89, 137-8.	1.7	2

#	Article	IF	Citations
451	Synergistic antiproliferative effect of recombinant interferon-gamma with recombinant interferon-alpha on chronic myelogenous leukemia hematopoietic progenitor cells (CFU-GEMM,) Tj ETQq1 1 0.784314 rgBT /Overlock 1	3.4	2
452	Liquid scintillation counting for 59Fe and 51Cr in erythrokinetic studies. The International Journal of Applied Radiation and Isotopes, 1980, 31, 35-36.	0.7	1
453	Meningeal Leukemia following Lymphoid Blast Crisis in Chronic Myeloid Leukemia: Therapeutic Implications. Tumori, 1982, 68, 257-263.	0.6	1
454	Role of Iron and Proteins of Iron Metabolism in Cell Growth. Current Studies in Hematology and Blood Transfusion, 1991, 58, 153-157.	0.2	1
455	Câ€FMS EXPRESSION IN Bâ€CELLS AND RESPONSE TO Mâ€CSF. British Journal of Haematology, 1993, 84, 755-756.	1.2	1
456	Evaluation of the Effects of Pefloxacin on Platelet AggregationIn VitroandEx Vivoin Patients Suffering from Chronic Bronchitis. Journal of Chemotherapy, 1995, 7, 38-41.	0.7	1
457	Recombinant human erythropoietin to assist autologous blood donation by patients with anemia. Translational Research, 1997, 130, 354-356.	2.4	1
458	Differential HFE allele expression in hemochromatosis heterozygotes. Gastroenterology, 2001, 120, 1308.	0.6	1
459	C023 Expression profiling of CD34+ cells in patients with myelodysplastic syndromes: differences between early and advanced cases and analysis of apoptosis-related genes. Leukemia Research, 2007, 31, S35.	0.4	1
460	P136 Treatment with erythropoietin and G-CSF improves survival in MDS patients with low transfusion need. Leukemia Research, 2007, 31, S113-S114.	0.4	1
461	New blood in Haematologica. Haematologica, 2011, 96, 1741-1742.	1.7	1
462	Molecular basis of myelodysplastic syndromes. Leukemia Supplements, 2012, 1, S35-S36.	0.1	1
463	Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. American Journal of Hematology, 2012, 87, 129-130.	2.0	1
464	Introduction to a review series on myeloproliferative neoplasms. Blood, 2017, 129, 659-659.	0.6	1
465	Identification of Aberrant Splicing Events in Myelodysplastic Syndrome Patients with Splicing Factor Gene Mutations. Leukemia Research, 2017, 55, S9.	0.4	1
466	A Rule-Based Expert System for Automatic Implementation of Somatic Variant Clinical Interpretation Guidelines. Lecture Notes in Computer Science, 2019, , 114-119.	1.0	1
467	Introduction to a review series on transfusion medicine. Blood, 2019, 133, 1793-1794.	0.6	1
468	Introduction to a How I Treat series on acquired hemolytic anemia. Blood, 2021, 137, 1269-1269.	0.6	1

#	Article	IF	Citations
469	LIQUID SCINTILLATION COUNTING FOR 59Fe AND 51Cr IN ERYTHROKINETIC STUDIES. , 1980, , 517-523.		1
470	Abnormal Regulation of Intracellular Calcium in Human Megakaryocytes Contributes to the Pathophysiology of Calr-Mutant Myeloproliferative Neoplasms. Blood, 2018, 132, 1782-1782.	0.6	1
471	Several Somatic Mutations of JAK2 Exon 12 Are Found in Patients with a JAK2 (V617F)-Negative Myeloproliferative Disorder That Is Mainly Characterized by Erythrocytosis.. Blood, 2007, 110, 263-263.	0.6	1
472	Loss of Heterozygosity of Chromosome 1p34 and High Mutant Allele Burden in Patients with Post-Essential Thrombocythemia Myelofibrosis Carrying Somatic Mutations of MPL. Blood, 2008, 112, 176-176.	0.6	1
473	Outcome of Refractory Anemia with Ringed Sideroblasts Associated with Marked Thrombocytosis (RARS-T) In a Large Cohort of Patients. Blood, 2010, 116, 4113-4113.	0.6	1
474	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. Blood, 2011, 118, 262-262.	0.6	1
475	Serum C-Terminal Telopeptide Maintains Its Correlation with Bone Disease in Myeloma Patients Even Under Treatment with Bisphosphonates. Blood, 2012, 120, 4003-4003.	0.6	1
476	NOTCH1, SF3B1 and TP53 Mutations in Fludarabine-Refractory CLL Patients Treated with Alemtuzumab: Results From the CLL2H Trial of the Gcllsg. Blood, 2012, 120, 710-710.	0.6	1
477	Splanchnic Vein Thrombosis Associated with Myeloproliferative Neoplasms: A Study of the AGIMM & IWG-MRT Groups in 519 Subjects. Blood, 2014, 124, 3163-3163.	0.6	1
478	Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin. Blood, 2014, 124, 3215-3215.	0.6	1
479	Prognostic Impact of Rare Single Abnormalities in Myelodysplastic Syndromes. Blood, 2015, 126, 2879-2879.	0.6	1
480	Fusion Gene Detection Using Whole Transcriptome Analysis in Patients with Chronic Myeloproliferative Neoplasms and Secondary Acute Myeloid Leukemia. Blood, 2015, 126, 4093-4093.	0.6	1
481	Natural history of idiopathic refractory sideroblastic anemia. Blood, 1988, 71, 305-312.	0.6	1
482	Familial-skewed X-chromosome inactivation as a predisposing factor for late-onset X-linked sideroblastic anemia in carrier females. Blood, 2000, 96, 4363-4365.	0.6	1
483	Clonal Origin of Circulating Endothelial Progenitor Cells in Patients with Myelofibrosis with Myeloid Metaplasia.. Blood, 2004, 104, 2427-2427.	0.6	1
484	Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes: A Prospective Validation Study in Low-Risk Patients with Normal Karyotype. Blood, 2008, 112, 3634-3634.	0.6	1
485	Identification of Prognostic Markers by Gene Expression Profiling In Myelodysplastic Syndrome Hematopoietic Stem Cells. Blood, 2010, 116, 298-298.	0.6	1
486	High Throughput Targeted Gene Sequencing in 738 Myelodysplastic Syndromes Patients Reveals Novel Oncogenic Genes, Rare Driver Mutations and Complex Molecular Signatures with Potential Impact for Patient Diagnosis and Prognosis in the Clinic. Blood, 2012, 120, LBA-5-LBA-5.	0.6	1

#	Article	IF	Citations
487	Prediction of Overall Survival in 520 Patients with Primary Myelofibrosis: Outcome Update of the Dynamic International Prognostic Scoring System (DIPSS) Patient Cohort. Blood, 2012, 120, 1729-1729.	0.6	1
488	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstroˆm Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. Blood, 2012, 120, 2667-2667.	0.6	1
489	THE USE OF PERIPHERAL-BLOOD HEMATOPOIETIC PROGENITORS MOBILIZED WITH STANDARD-DOSE CHEMOTHERAPY PLUS GRANULOCYTE-COLONY-STIMULATING FACTOR TO SUPPORT MULTICYCLIC DOSE-INTENSIVE CHEMOTHERAPY FOR ADVANCED BREAST-CANCER. Oncology Reports, 1995, 2, 1075-8.	1.2	1
490	Whole Exome Sequencing Identifies Novel MPL and JAK2 M utations in Triple Negative Myeloproliferative Neoplasms. Blood, 2015, 126, 606-606.	0.6	1
491	Common Variation at 6q25.3 (TULP4) Influences Risk for Arterial Thrombosis in Myeloproliferative Neoplasms. Blood, 2015, 126, 4088-4088.	0.6	1
492	VD Versus VTD Induction: Similar Efficacy in Controlling Disease in Transplant Eligible Multiple Myeloma Patients Outside Clinical Trials. Blood, 2016, 128, 5711-5711.	0.6	1
493	Introduction to a Review Series on Normal and Pathologic Erythropoiesis. Blood, 2022, , .	0.6	1
494	Flomoxef, a new oxacephem antibiotic, does not cause hemostatic defects. The International Journal of Clinical Pharmacologyrapy, and Toxicology, 1993, 31, 148-52.	0.1	1
495	Analysis of Factors Predicting Response to Recombinant Human Erythropoietin in Nonrenal Anaemia. Leukemia and Lymphoma, 1992, 7, 100-100.	0.6	0
496	Sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following intensified, accelerated CEE (cyclophosphamide, epirubicin, etoposide) chemotherapy in patients with solid tumors. International Journal of Oncology, 1996, 9, 971-6.	1.4	0
497	[30] Inhibition of c-ABL expression in hematopoietic progenitor cells using antisense oligodeoxynucleotides. Methods in Enzymology, 2000, 314, 429-440.	0.4	0
498	Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 2004, 125, 99-100.	1.2	0
499	20 Refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia Research, 2009, 33, S15-S16.	0.4	0
500	YI1 Gene expression profiling of day 7 erythroblasts from refractory anemia with ringed sideroblasts (RARS) and microarray-based identification of erythroid granulocyte-CSF (G-CSF) targets. Leukemia Research, 2009, 33, S55.	0.4	0
501	P036 Diagnostic utility of flow cytometry in myelodysplastic syndromes lacking conventional diagnostic markers: a prospective validation study. Leukemia Research, 2009, 33, S79.	0.4	0
502	A translational link between Fe and Epo. Blood, 2013, 122, 1538-1539.	0.6	0
503	Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells InÂVivo. Cancer Cell, 2015, 27, 603-605.	7.7	0
504	Clinical Phenotype and Genotype Correlations with Time to Progression into Post Polycythemia Vera and Post Essential Thrombocythemia Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S354-S355.	0.2	0

#	Article	IF	Citations
505	Introduction to a How I Treat series on anemia. Blood, 2020, 136, 773-774.	0.6	0
506	Use of recombinant human erythropoietin in the treatment of myelodysplastic syndromes. , 2002, , 235-239.		0
507	Flow Cytometry Evaluation of Erythroid Dysplasia in Patients with Myelodysplastic Syndrome.. Blood, 2004, 104, 2365-2365.	0.6	0
508	Prospective Clinical and Epidemiological Evaluation of rHuEPO in the Routine Care of a Network of Hematological Centers.. Blood, 2004, 104, 5290-5290.	0.6	0
509	Gene Expression Profiling Defines a Set of New Molecular Markers for Sporadic and Familial Myeloproliferative Disorders.. Blood, 2004, 104, 657-657.	0.6	0
510	Sequential Evaluation of the Proportion of Granulocyte JAK2 (V617F) Mutant Alleles in Chronic Myeloproliferative Disorders.. Blood, 2006, 108, 2682-2682.	0.6	0
511	High-Resolution Genomic Profiling of Myelodysplasia (MDS) by Microarray Comparative Genomic Hybridization (CGH).. Blood, 2006, 108, 2645-2645.	0.6	0
512	Expression Profiling of CD34+ Cells in Patients with Myelodysplastic Syndromes: Involvement of Interferon-Stimulated Genes and Correlation to FAB Subtype and Karyotype.. Blood, 2006, 108, 2626-2626.	0.6	0
513	Haploinsufficiency of RPS14 and Deregulation of Ribosomal- and Translation-Related Genes in MDS Patients with Del(5q). Blood, 2008, 112, 3641-3641.	0.6	0
514	The Effects of Mitochondrial Ferritin Expression in Normal and Sideroblastic Erythropoiesis.. Blood, 2009, 114, 736-736.	0.6	0
515	INCB018424, a Selective Inhibitor of JAK1 and JAK2, Downregulates the Expression of Leukocyte Alkaline Phosphatase (LAP) On Circulating Granulocytes in Patients with Polycythemia Vera and Essential Thrombocythemia.. Blood, 2009, 114, 2905-2905.	0.6	0
516	Fotemustine IN COMBINATION with BORTEZOMIB and DEXAMETHASONE: Encouraging PRELIMINARY RESULTS FROM A PHASE II STUDY On Relapsed REFRACTORY MYELOMA PATIENTS. Blood, 2010, 116, 3037-3037.	0.6	0
517	Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004). Blood, 2010, 116, 4027-4027.	0.6	0
518	Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2881-2881.	0.6	0
519	Clonal Analysis of SF3B1, JAK2 and MPL in Refractory Anemia with Ring Sideroblasts Associated with Marked Thrombocytosis. Blood, 2012, 120, 172-172.	0.6	0
520	Fotemustine (MUFORAN) in Combination with Once Weekly Bortezomib and Dexamethasone (B-MuD): Good Clinical Activity and Favourable Toxicity Profile for Treatment of Relapsed Multiple Myeloma Patients.. Blood, 2012, 120, 2957-2957.	0.6	0
521	Identification of Gene Expression Based Prognostic Markers in the Hematopoietic Stem Cells of Patients with Myelodysplastic Syndromes. Blood, 2012, 120, 3857-3857.	0.6	0
522	Efficacy of Ruxolitinib in Chronic Eosinophilic Leukemia Associated with t(8;9)(p22;p24) and PCM1-JAK2 Fusion Gene.. Blood, 2012, 120, 2833-2833.	0.6	0

#	Article	IF	Citations
523	Genetic Determinants Of Disease Phenotype In Myelodysplastic Syndromes. Blood, 2013, 122, 2755-2755.	0.6	0
524	Congenital Erythropoietin-Dependent Erythrocytosis Responsive to Theophylline Treatment. Blood, 1998, 91, 360-362.	0.6	0
525	Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients. Blood, 2014, 124, 633-633.	0.6	0
526	Genetic Determinants of Disease Phenotype and Clinical Outcome in Myelodysplastic Syndromes with Ring Sideroblasts. Blood, 2014, 124, 825-825.	0.6	0
527	Evidence of ETNK1 Somatic Variants in Atypical Chronic Myeloid Leukemia. Blood, 2014, 124, 2212-2212.	0.6	0
528	Low Risk IPSS/DIPSS Primary Myelofibrosis: Identification of Patients with Higher Risk of Progression. Blood, 2014, 124, 3187-3187.	0.6	0
529	Real Life Analysis of the Rete Ematologica Lombarda on ELN Favorable Acute Myeloid Leukemia: The Molecular Remission Is a Necessary Goal for a Good Outcome in All Different Cytogenetic/Molecular Subgroups. Blood, 2015, 126, 3740-3740.	0.6	0
530	Whole Exome Sequencing Reveals Clonal Evolution of Myeloproliferative Neoplasms to Acute Myeloid Leukemia. Blood, 2015, 126, 1626-1626.	0.6	0
531	The Impact of Driver Mutations of JAK2, Calr, or MPL in Patients with Myelofibrosis Undergoing Hemopoietic Stem Cell Transplantation. Blood, 2015, 126, 5405-5405.	0.6	0
532	IWG-MRT 2013 Criteria-Based Assessment of Response Among 83 Patients with Myelofibrosis Treated with JAK Inhibitors: Experience of Two Centers. Blood, 2015, 126, 1615-1615.	0.6	0
533	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. Blood, 2015, 126, 5084-5084.	0.6	0
534	Combined DNA and Transcriptome Sequencing Reveals Discrete Subtypes of Myelodysplasia. Blood, 2016, 128, 1974-1974.	0.6	0
535	Rearrangements of Tyrosine Kinase (TK) Genes in Chronic Myeloproliferative Disorders (CMPD): A FISH Study. Blood, 2016, 128, 5493-5493.	0.6	0
536	Impact of Switching from Intravenous to Subcutaneous Bortezomib in Real Life. Overlapping Toxicity and Efficacy in All Settings of Myeloma Patients Balancing Schedule and Way of Bortezomib Adminisration. Blood, 2016, 128, 5695-5695.	0.6	0
537	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 53-53.	0.6	0
538	Genome-Wide Analysis of Non-Coding Alterations in Pan-Myeloid Cancers Using Whole Genome Sequencing. Blood, 2018, 132, 103-103.	0.6	0
539	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	0.6	0
540	Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients. Blood, 2018, 132, 3039-3039.	0.6	0

#	Article	IF	Citations
541	Impact of Bone Marrow Fibrosis Grade in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis. a Study of the Mysec Group. Blood, 2019, 134, 2946-2946.	0.6	0
542	RNA missplicing and ring sideroblasts in MDS. Blood, 2022, 139, 1933-1935.	0.6	0